Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558012 | 1.00 | LMNA (0.44) | LMNADRD2SIGMAR1FPR2CHRM2 | |
| SCHEMBL3561969 | 0.85 | SIGMAR1 (0.41) | DRD2SIGMAR1FPR2CHRM2CHRM3 | |
| SCHEMBL3561974 | 0.85 | SIGMAR1 (0.41) | DRD2SIGMAR1FPR2CHRM2CHRM3 | |
| SCHEMBL3557221 | 0.82 | LMNA (0.42) | LMNADRD2FPR2CHRM2CHRM3 | |
| SCHEMBL3557220 | 0.82 | LMNA (0.42) | LMNADRD2FPR2CHRM2CHRM3 | |
| SCHEMBL3555405 | 0.81 | DRD2 (0.45) | DRD2SIGMAR1CHRM2CHRM3TACR1 | |
| SCHEMBL3553614 | 0.81 | DRD2 (0.45) | DRD2SIGMAR1CHRM2CHRM3TACR1 | |
| SCHEMBL3553840 | 0.81 | DRD2 (0.39) | DRD2SIGMAR1CHRM2CHRM3TACR1 | |
| SCHEMBL3553837 | 0.81 | DRD2 (0.39) | DRD2SIGMAR1CHRM2CHRM3TACR1 | |
| SCHEMBL3554180 | 0.77 | DRD2 (0.41) | LMNADRD2SIGMAR1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | LMNA 3911/4885DRD2 47/4885SIGMAR1 249/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | LMNA 3803/4885DRD2 45/4885SIGMAR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.